Saurabh Chaubey
Shots:
In a retrospective study sourced from EHR data for DLBCL patients, groundbreaking insights were unearthed that could potentially shape the treatment landscape of CAR-T Therapies in DLBCL
Data from the 10-year study is divided into pre- and post-CAR-T eras to better reflect trends in patient demographics and disease progression
PharmaShots welcomes Dr. Ira Zackon,…
Shots:
In the five-year follow-up data from the randomized POLARIX study, where participants received R-CHOP with a placebo for polatuzumab (control arm) and Pola-R-CHP with a placebo for vincristine
The primary endpoint of the study was progression free survival, and the secondary endpoint was overall survival
PharmaShots welcomes Dr. John Burke from Rocky Mountain Cancer…
Shots:
Did you know that coronary stent usage can decline by 20 percent if GLP-1 therapy is used as widely as statin therapy?
PharmaShots welcomes Saif Rathore, Founder of Sandbar Life Sciences and Entrepreneur-in-Residence at Yale Ventures, and Andrew Epstein, Principal at Medicus Economics, for an illuminating dialogue exchange
Saif and Andrew highlight the untapped…
Shots:
Recently, at ASH 2024, Takeda presented data from several ongoing clinical trials across hematology and oncology, including the Phase II OPTIC and Phase III PhALLCON studies, among others
Phuong Khanh Morrow, Head of the Oncology Therapeutic Area Unit at Takeda, shed light on Takeda’s key presentations at ASH 2024
Phuong also highlighted the findings…
Shots:
Recently, the groundbreaking results from Galderma’s Phase III OLYMPIA 1 trial were published in JAMA Dermatology. The study evaluated nemolizumab in patients with moderate-to-severe active prurigo nodularis
The trial met all primary and secondary endpoints, with results aligning with those from the OLYMPIA 2 trial, reinforcing nemolizumab’s potential in achieving sustained improvements in the…
Shots:
Identifying discrepancies remains a key challenge for manufacturers in mitigating revenue leakage and ensuring alignment with payer plans
Suresh Kannan, Model N’s Chief Product Officer, offers insights into the newly launched GenAI and enhanced data solutions aimed at optimizing revenue and ensuring compliance
He also outlines a strategic approach to formulary identification and emphasizes…
Shots:
Research into Lupus has yielded groundbreaking results in pharmacokinetics and pharmacodynamics, yet experts still don't understand its cause
Lupus Research Alliance (LRA) recently launched a platform called Data Repository, Exchange, and Analytics (DREAM) for data sharing and partnerships for research in lupus
Devon Kelly, Director of Lupus Nexus at the Lupus Research Alliance, sheds…
HLTH Europe is the continent’s #1 healthcare innovation event. Following an enormously successful first event in 2024 and the exponential growth of HLTH in the US, this landmark event is where global expertise meets local insight to address Europe's unique healthcare challenges and opportunities.
Don’t miss out on this opportunity to connect with like-minded individuals…
Shots:
AATD-associated liver disease is a progressive genetic disorder with no approved therapy, and liver transplantation remains the only option for patients with end-stage disease.
Fazirsiran is an investigational RNAi therapy designed to treat AATD-associated liver disease by lowering the production of Z-AAT.
PharmaShots welcomes Dr. Chinwe Ukomadu, Head of the Gastrointestinal and Inflammation Therapeutic…